Cargando…
Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers
PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recu...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974697/ https://www.ncbi.nlm.nih.gov/pubmed/31993510 http://dx.doi.org/10.1016/j.ctro.2019.12.005 |